Home
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Supplements
Categories
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In The News
Online First
Videos
About
About VBCR
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Author Guidelines
Thursday, 28 March 2024
Medical Writer
Authored Items
Xeljanz/Xeljanz XR (Tofacitinib/Tofacitinib XR), an Oral JAK Inhibitor, Now Approved for Adults with Active Psoriatic Arthritis
Loretta Fala
VBCR - April 2018, Vol 7, No 1
in
Drug Updates
Siliq (Brodalumab) a New IL-17RA Antagonist Approved for Moderate-to-Severe Plaque Psoriasis
Loretta Fala
VBCR - December 2017, Vol 6, No 5
in
Drug Updates
Kevzara (Sarilumab), a New IL-6 Receptor Antagonist Approved for Moderately to Severely Active Rheumatoid Arthritis
Loretta Fala
VBCR - August 2017, Vol 6, No 3
in
Drug Updates
Cosentyx (Secukinumab) First IL-17A Antagonist Approved for the Treatment of Patients with Psoriatic Arthritis or Ankylosing Spondylitis
Loretta Fala
VBCR - December 2016, Vol 5, No 6
in
Drug Updates
Taltz (Ixekizumab), IL-17A Antagonist, Receives FDA Approval for Patients with Plaque Psoriasis
Loretta Fala
VBCR - October 2016, Vol 5, No 5
in
Drug Updates
Zinbryta (Daclizumab): First Once-Monthly, Self-Administered Treatment Approved for Patients with Multiple Sclerosis
Loretta Fala
VBCN - July 2016 Volume 3, No 2
in
Drug Updates
Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Loretta Fala
VBCN - May 2015 Volume 2, No 1
in
Drug Updates
Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Loretta Fala
VBCC - May 2015, Vol 6, No 4
in
Drug Updates
Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer
Loretta Fala
VBCC - April 2015, Vol 6, No 3
in
Drug Updates
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer
Loretta Fala
VBCC - March 2015, Vol 6, No 2
in
Drug Updates
Rasuvo (Methotrexate) Once-Weekly Subcutaneous Injection with Flexible Dosing Approved by the FDA for Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, and Severe Psoriasis
Loretta Fala
VBCR - December 2014, Volume 3, No 6
in
Drug Updates
Velcade (Bortezomib) Receives New FDA Indication for Retreatment in Patients with Multiple Myeloma
Loretta Fala
Value-Based Care in Myeloma
in
Drug Updates
,
Multiple Myeloma
Higher Dose, Fewer Weekly Injections of Copaxone (Glatiramer Acetate) Approved by the FDA for Patients with Relapsing Forms of Multiple Sclerosis
Loretta Fala
VBCN - July 2014 Volume 1, No 2
in
Drug Updates
Tafinlar (Dabrafenib)/Mekinist (Trametinib) Combination Therapy Received Accelerated FDA Approval for the Treatment of Patients with Metastatic Melanoma
Loretta Fala
VBCC - June 2014 Vol 5, No 5
in
Drug Updates
Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis
Loretta Fala
VBCR - June 2014, Volume 3, No 3
in
Drug Updates
Last modified: July 1, 2014
Home
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Supplements
Categories
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In The News
Online First
Videos
About
About VBCR
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Author Guidelines